Moderna Competitors and Similar CompaniesClear all

Moderna's competitors and similar companies include CureVac and Alnylam Pharmaceuticals.
Moderna
Moderna
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
CureVac
CureVac
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Founding Date
Founding Date
2010
Founding Date
2000
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Melbourne, AU
Paris, FR
München, DE
Tokyo, JP
Seoul, KR
Warszawa, PL
see more
Locations
Tübingen, DE HQ
Ottignies Louvain La Neuve, BE
Wiesbaden, DE
Amsterdam, NL
Basel, CH
Boston, US
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Employees
Employees
5,60044% increase
Employees
904
Employees
1,32324% increase
Valuation ($)
Valuation ($)
55.1 b
Valuation ($)
666.2 m
Valuation ($)
19 b
Twitter followers
Twitter followers
151.2 k
Twitter followers
12
Twitter followers
16.3 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
17
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
23
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
39.6
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
3
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
86.96%

Financial

Revenue (est.)
Revenue (est.)
$6.8b (FY, 2023)
Revenue (est.)
€53.8m (FY, 2023)
Revenue (est.)
$1.8b (FY, 2023)
Cost of goods
Cost of goods
$4.7b (FY, 2023)
Cost of goods
€83.4m (FY, 2023)
Cost of goods
$268.2m (FY, 2023)
Gross profit
Gross profit
$2.2b (FY, 2023)
Gross profit
(€21.7m) (FY, 2023)
Gross profit
$1.6b (FY, 2023)
Net income
Net income
($4.7b) (FY, 2023)
Net income
(€260.2m) (FY, 2023)
Net income
($440.2m) (FY, 2023)

Operating

Patent Applications
Patent Applications
430 (FY, 2021)
Patent Applications
500 (Mar, 2020)
Patent Applications
N/A
Patents Issued
Patents Issued
270 (FY, 2020)
Patents Issued
233 (May, 2020)
Patents Issued
N/A

Funding

Total funding raised
Total funding raised
$ 1.8b
Total funding raised
$ 1.1b
Total funding raised
$ 1.5b
For sources of this data, please see the company profile

View Company Profiles

CureVac
HQ
Tübingen, DE
Employees
904

CureVac is a biotechnology company offering messenger RNA (mRNA) technology.

View company
Alnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

View company